

Annual report of the Executive Board

10th EMAV ordinary General Assembly on 7th of May 2025 in Berlin/ Germany

- Peter Behr summarized that the association was faced with a number of new challenges in the reporting period, which could be mastered successfully with a continued goal-oriented work, a well-operating and committed team and by using an established network.
- Core activities of EMAV included (a) the close consultation of EMAV in particular with the European Commission in the changed process and timeline for the implementation of the Reg. (EU) 2019/6 for autogenous vaccines and for the publication of a GMP standard for autogenous vaccines, (b) the work on new EMAV projects, like for the rationales for the EMAV GMP proposal, for the new/updated EMAV ROADMAP and for epidemiological issues, (c) the profiling of a newly composed Board of Directors and the admission of new EMAV members and (d) a number of follow-up activities from the EMAV meeting in April 2024 in Barcelona.
- In more detail the following core activities and milestones have been presented:
 - EMAV's 9th General Assembly on 24th of April 2024 in Barcelona
 - EMAV's 8th EMAV Workshop on 23rd of April 2024 in Barcelona
 - Membership issues
 - Status implementation of Implementing Act/GMP by the EC
 - Developments regarding the legal framework for AV in EU Member states
 - Project activities of SWG/Board for the development of rationales in addition to the EMAV GMP proposal
 - Evaluation for a EMAV ROADMAP 2025-2028
 - Preparations for EMAV meetings in Berlin, 6th/7th of May 2025
 - EMAV stakeholder activities with EC/ EMA/ GMDP-IWG/ PIC/s/ IABS/ other stakeholders
 - EMAV communication activities
 - Financial status / Cash Audit
 - Board activities
- The report presented by Peter Behr contained the main activities of the Executive Board and the Management Board during the reporting period. Additional information can be provided by the managing director.

May, ^{8th}, 2025

Dr. Klaus-Peter Behr
Chairman

Dr. Gerfried Zeller
Managing Director

08/05/2025 // Dr. KPB / Dr. GZ

*European Manufacturers of Autogenous Vaccines and Sera - EMAV e.V. | Geyerspergerstr. 27 | 80689 München | Germany
Amtsgericht München Register-Nr.: 207990 | USt-IdNr.: DE32 3904 802*

Board: Dr. Klaus-Peter Behr (Chair), Maarten de Gussem/DVM (Dep Chair), Dr. Astrid Weiss, Javier Sanz Martin/DVM, Mr. Jean-Charles Tissot

Managing Director: Dr. Gerfried Zeller

EMAV e.V. listed at EC Transparency Register, ID nb. 224469535841-56